Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment

Table 2

Laboratory and clinical findings of RA patients treated with tocilizumab (TCZ) and methotrexate (MTX).

	TCZ pts. ()			MTX pts. ()
(Mean ± SD)	Baseline	24 weeks	52 weeks	Baseline	24 weeks	52 weeks
ESR (mm/h)	64 ± 23	17 ± 9	15 ± 7	57 ± 23	13 ± 12	12 ± 10
CRP (mg/l)	7.3 ± 3.2	1.1 ± 3	0.9 ± 2.7	6.8 ± 1.9	3.5 ± 4§	1.7 ± 1§
DAS28	5.3 ± 0.4	2.5 ± 1.6	2.2 ± 1.1	4.9 ± 1.5	2.6 ± 1.8	1.9 ± 0.8
CDAI	28.9 ± 2.1	6.1 ± 1.1	4.7 ± 1	26.6 ± 8.6	9 ± 1.4	5.2 ± 1.1
HAQ	1.7 ± 0.5	0.8 ± 0.4	0.7 ± 0.5	1.2 ± 0.7§	0.4 ± 0.3§	0.2 ± 0.5§
Total cholesterol (mg/dl)	210 ± 21	235 ± 23†	223 ± 24	189 ± 38	188 ± 35§	192 ± 38§
Non-HDL cholesterol (mg/dl)	166 ± 18	187 ± 16†	172 ± 14	156 ± 27	146 ± 25§	142 ± 19§
LDL cholesterol (mg/dl)	146 ± 13	161 ± 11†	151 ± 12	128 ± 22§	117 ± 25§	118 ± 15§
Triglycerides (mg/dl)	139 ± 14	157 ± 15†	148 ± 14	126 ± 26§	121 ± 24§	123 ± 22§
HDL cholesterol (mg/dl)	43 ± 11	52 ± 11†	45 ± 12	50 ± 14	48 ± 12	51 ± 10
Total/HDL cholesterol ratio	4.9 ± 0.22	4.75 ± 0.23	4.75 ± 0.18	3.6 ± 0.9§	3.8 ± 0.8§	3.5 ± 0.7§
LDL/HDL cholesterol ratio	3.22 ± 0.17	3.25 ± 0.22	3.21 ± 0.2	2.2 ± 0.6§	2.5 ± 0.9§	2.1 ± 0.5§
AIP (log10 TG/HDL)	0.51 ± 0.3	0.48 ± 0.4	0.52 ± 0.4	0.4 ± 0.3§	0.4 ± 0.2§	0.38 ± 0.4§

AIP: atherogenic index of plasma; CRP: C-reactive protein; ESR: erytro-sedimentation rate; DAS28: 28-joint disease activity score; CDAI: clinical disease activity index; HAQ: Health Assessment Questionnaire; HDL: high-density lipoprotein; LDL: low-density lipoprotein; TG: triglycerides. Univariate analysis: vs. baseline; vs. TCZ. Multivariate analysis: .